AUSTIN (Nexstar) \u2014 A program designed to conduct drug development clinical trials for a psychedelic drug in Texas hit a road bump after the state could not find a drug company to help develop a FDA-approved drug.<\/p>\n
Lt. Gov. Dan Patrick and Texas House Speaker Dustin Burrows jointly announced the state would proceed with its own research program on Tuesday.<\/p>\n
\u201cWe intend to fully fund this program, and will work in partnership with our great medical research teams in Texas to conduct the research,\u201d the joint statement from the leaders of the Texas legislature read.<\/p>\n
Last year the legislature almost unanimously passed a bill that directs the Texas Health and Human Services Commission (HHSC) to oversee a program that would research a psychedelic drug called ibogaine and develop a FDA-approved drug.<\/p>\n
Notable veterans, like retired U.S. Navy SEAL Marcus Luttrell, lobbied lawmakers to create some support for the drug. Ibogaine is currently a Schedule 1 drug in the United States. Ibogaine is a \u201cplant-based psychoactive substance derived from the iboga shrub, a plant native to Central Africa,\u201d according to UTHealth Houston. In 2024, a study by Stanford University found ibogaine has potential to effectively treat patients with traumatic brain injuries.<\/p>\n
Luttrell traveled to Mexico to receive treatment of ibogaine. \u201cI took that medication and I laid down that night,\u201d Luttrell told lawmakers in a committee hearing in 2025. \u201cI woke up the next morning and I had no appetite for opioids. I had no appetite for alcohol.\u201d<\/p>\n
Ibogaine advocate Bryan Hubbard has been pushing for more support of ibogaine around the country. Even with the setback in Texas, Hubbard commended leadership\u2019s position to fully fund the program.<\/p>\n
\u201cThis is about life or death, and the Texas commitment reflects the seriousness of the calls that we are here to see through to the end,\u201d Hubbard said.<\/p>\n
The state decided to allocate $50 million to a grant program controlled by Texas HHSC. The commission selected UTHealth Houston and the University of Texas Medical Branch at Galveston to lead the multi-year clinical trials along with hospitals and a drug developer. The universities will study the effects of ibogaine on patients with addiction, traumatic brain injuries, and other behavioral health conditions.<\/p>\n
Unfortunately the state was unable to find a drug developer that met the requirements laid out in the statute. Drug companies would have to match the state investment, maintain a commercial presence in Texas, give the state 20% of the profits from any drug it developed from the trials, among other requirements.<\/p>\n
Katharine Harris, a drug policy fellow at Rice University\u2019s Baker Institute for Public Policy, said she did not find it surprising the state could not find a developer to meet those requirements.<\/p>\n
\u201cWe\u2019re talking about a research area that is relatively high risk at the FDA level and also on the scientific and medical side,\u201d Harris explained.<\/p>\n
The next steps for the program remain unclear at this point. Harris said the statute only allows the $50 million state investment to be released after private donations have matched that amount. It\u2019s unclear at this point if any money has been privately raised to help fund the program. Harris said in order for the drug to reach FDA-approval will likely cost more than $100 million.<\/p>\n
\u201cSo that\u2019s another open question here is how much how much of state resources is Texas willing to commit to this project,\u201d Harris said.<\/p>\n
Harris added that she has confidence the universities that are part of the program are more than capable to conduct the clinical trials, but she\u2019s unaware if the state has ever solely gone through the FDA-approval process for a drug.<\/p>\n
\u201cIt\u2019s typically an area that we have ceded to the private industry,\u201d Harris explained.<\/p>\n
Nexstar reached out to Patrick\u2019s office to ask about the next steps for the program. A spokesperson in his office said Patrick was unable to speak with a reporter this week.<\/p>\n
Copyright 2026 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.<\/p>\n